Earlier this week, Lpath, Inc. was awarded a $1.45 million grant by the Department of Defense to conduct further preclinical studies of a medication intended to ease the pain associated with traumatic brain injury. The pill, Lpathomab, “is a first-in-class, humanized monoclonal antibody targeting lysophosphatidic acid”. To date, Lpathomab has only been tested in animals and humans who have not suffered a TBI, both with positive results. Presumptively, these new funds will help them test its effects in the people that it is intended to help. This new government grant, with its potentially positive implications, resulted in the Lpath stock rising by 62% earlier this week.